Chiara Nozzoli

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Alessandra Larocca, Davide Rossi, Maide Cavalli et al. · Blood · 2010 · 382 citations · Full text

Medicine, Hematology, Pharmacology +14

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo, Michèle Cavo, Elena Zamagni et al. · Journal of Clinical Oncology · 2011 · 322 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michèle Cavo, Lucia Pantani, Maria Teresa Petrucci et al. · Blood · 2012 · 309 citations · Full text

Medicine, Hematology, Pharmacotherapy +16